{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:07:07Z","timestamp":1789056427107,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001688","name":"International Centre for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007675","name":"International Center for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007675","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201793","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:39:08Z","timestamp":1781912348000},"page":"201793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapamycin nanoparticles mitigate anti-AAV antibody formation in a mouse model of ornithine transcarbamylase deficiency"],"prefix":"10.1016","volume":"34","author":[{"given":"Antonio","family":"Vicidomini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Boisgerault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Guarnaccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Collaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro R.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"de Sabbata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novella","family":"Tedesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Lisjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshi","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Camparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iaconcig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Skoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Ilyinskii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Brunetti-Pierri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bortolussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ronzitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi Kei","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9628-0494","authenticated-orcid":false,"given":"Andr\u00e9s F.","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201793_bib1","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.ymgme.2010.01.014","article-title":"Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium","volume":"100","author":"Seminara","year":"2010","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omta.2026.201793_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymgme.2014.08.001","article-title":"A longitudinal study of urea cycle disorders","volume":"113","author":"Batshaw","year":"2014","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omta.2026.201793_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0266-1","article-title":"Long-term outcomes in Ornithine Transcarbamylase deficiency: a series of 90 patients","volume":"10","author":"Brassier","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omta.2026.201793_bib4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/jhg.2015.54","article-title":"Clinical outcomes and the mutation spectrum of the OTC gene in patients with ornithine transcarbamylase deficiency","volume":"60","author":"Choi","year":"2015","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.omta.2026.201793_bib5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa2214084","article-title":"Gene Therapy in Patients with the Crigler-Najjar Syndrome","volume":"389","author":"D'Antiga","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201793_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201793_bib7","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201793_bib8","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII Gene Transfer in Severe Hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201793_bib9","first-page":"668","article-title":"Long-Term Safety and Urea Cycle Function Following a Phase 1\/2 Trial of DTX301 in Adults with Late-Onset Ornithine Transcarbamylase (OTC) Deficiency","volume":"32","author":"Harding","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201793_bib10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/mt.2008.72","article-title":"Gene delivery to the juvenile mouse liver using AAV2\/8 vectors","volume":"16","author":"Cunningham","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201793_bib11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","article-title":"Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape","volume":"4","author":"Mingozzi","year":"2017","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omta.2026.201793_bib12","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201793_bib13","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201793_bib14","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/bloodadvances.2019000380","article-title":"Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates","volume":"3","author":"Salas","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201793_bib15","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201793_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omta.2026.201793_bib17","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201793_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1375","article-title":"Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies","volume":"11","author":"Ros-Ga\u00f1\u00e1n","year":"2022","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.omta.2026.201793_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.omtm.2017.01.003","article-title":"Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting","volume":"4","author":"Velazquez","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201793_bib20","article-title":"Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy","volume":"5","author":"Weber","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.omta.2026.201793_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omtm.2021.06.015","article-title":"ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia","volume":"22","author":"Ilyinskii","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201793_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgad394","article-title":"Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents","volume":"2","author":"Ilyinskii","year":"2023","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.omta.2026.201793_bib23","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201793_bib24","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/mt.2012.84","article-title":"Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B","volume":"20","author":"Mingozzi","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201793_bib25","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201793_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd0321","article-title":"Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles","volume":"7","author":"Ilyinskii","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omta.2026.201793_bib27","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nnano.2016.135","article-title":"Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles","volume":"11","author":"Kishimoto","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omta.2026.201793_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cellimm.2015.11.004","article-title":"Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation","volume":"301","author":"Zhang","year":"2016","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.omta.2026.201793_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101363","article-title":"Repeated dosing of AAV-mediated liver gene therapy in juvenile rat and mouse models of Crigler-Najjar syndrome type I. Molecular therapy","volume":"32","author":"Shi","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201793_bib30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.omtm.2020.11.005","article-title":"Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector","volume":"20","author":"De Sabbata","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201793_bib31","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1089\/hum.2013.233","article-title":"Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome","volume":"25","author":"Bortolussi","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201793_bib32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/hum.2011.183","article-title":"Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector","volume":"23","author":"Wang","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201793_bib33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1073\/pnas.1714670115","article-title":"Enhancement of hepatic autophagy increases ureagenesis and protects against hyperammonemia","volume":"115","author":"Soria","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201793_bib34","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013158","article-title":"Beclin-1-mediated activation of autophagy improves proximal and distal urea cycle disorders","volume":"13","author":"Soria","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omta.2026.201793_bib35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1034\/j.1600-0676.2002.01702.x","article-title":"Cell proliferation and renewal of normal hepatocytes and bile duct cells in adult mouse liver","volume":"22","author":"Magami","year":"2002","journal-title":"Liver"},{"key":"10.1016\/j.omta.2026.201793_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.30802\/AALAS-JAALAS-20-000020","article-title":"Reference Values for Hematology, Plasma Biochemistry, Bone Marrow Cytology and Bone Histology of NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)\/SzJ Immunodeficient Mice","volume":"60","author":"Layssol-Lamour","year":"2021","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"10.1016\/j.omta.2026.201793_bib37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jhep.2013.04.004","article-title":"Monogenic diseases that can be cured by liver transplantation","volume":"59","author":"Fagiuoli","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omta.2026.201793_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jimd.12709","article-title":"Liver-directed gene therapy for inherited metabolic diseases","volume":"47","author":"Baruteau","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omta.2026.201793_bib39","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/mt.2009.88","article-title":"AAV2\/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice","volume":"17","author":"Cunningham","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201793_bib40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cels.2022.05.001","article-title":"Diploid hepatocytes drive physiological liver renewal in adult humans","volume":"13","author":"Heinke","year":"2022","journal-title":"Cell Syst."},{"key":"10.1016\/j.omta.2026.201793_bib41","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.tibtech.2022.11.006","article-title":"Evading and overcoming AAV neutralization in gene therapy","volume":"41","author":"Earley","year":"2023","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.omta.2026.201793_bib42","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human Immune Responses to Adeno-Associated Virus (AAV) Vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201793_bib43","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201793_bib44","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2174\/156652307782151425","article-title":"Immune responses to AAV in clinical trials","volume":"7","author":"Mingozzi","year":"2007","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omta.2026.201793_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.08.022","article-title":"Lethality rescue and long-term amelioration of a citrullinemia type I mouse model by neonatal gene-targeting combined to SaCRISPR-Cas9","volume":"31","author":"Lisjak","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201793_bib46","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201793_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.637469","article-title":"Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles","volume":"12","author":"Ilyinskii","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201793_bib48","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41598-020-57893-z","article-title":"Capsid-specific removal of circulating antibodies to adeno-associated virus vectors","volume":"10","author":"Bertin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201793_bib49","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201793_bib50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fimmu.2018.00230","article-title":"Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance","volume":"9","author":"Kishimoto","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201793_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103125","article-title":"Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease","volume":"140","author":"Kishimoto","year":"2023","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.omta.2026.201793_bib52","doi-asserted-by":"crossref","first-page":"10770","DOI":"10.1073\/pnas.0902269106","article-title":"Cellular immune response to cryptic epitopes during therapeutic gene transfer","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201793_bib53","article-title":"Overcoming AAV8 Immunity: First Seropositive Crigler-Najjar Patient Treated with GNT0003 Following Imlifidase Pretreatment (GNT-018-IDES clinical trial)","author":"Labrune","year":"2025","journal-title":"Hum Gene Ther."},{"key":"10.1016\/j.omta.2026.201793_bib54","author":"Ronzitti"},{"key":"10.1016\/j.omta.2026.201793_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101216","article-title":"B cell focused transient immune suppression protocol for efficient AAV readministration to the liver. Molecular therapy","volume":"32","author":"Rana","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201793_bib56","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1080\/15548627.2018.1444312","article-title":"Targeting autophagy for therapy of hyperammonemia","volume":"14","author":"Soria","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.omta.2026.201793_bib57","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/jimd.12061","article-title":"Ammonia and autophagy: An emerging relationship with implications for disorders with hyperammonemia","volume":"42","author":"Soria","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omta.2026.201793_bib58","article-title":"Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases","volume":"5","author":"De Caneva","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.omta.2026.201793_bib59","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature13864","article-title":"Promoterless gene targeting without nucleases ameliorates haemophilia B in mice","volume":"517","author":"Barzel","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201793_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2022.785698","article-title":"Promoterless Gene Targeting Approach Combined to CRISPR\/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice","volume":"4","author":"Lisjak","year":"2022","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.omta.2026.201793_bib61","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/hep.31570","article-title":"Promoterless, Nuclease-Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia","volume":"73","author":"Chandler","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.omta.2026.201793_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf961","article-title":"High-efficiency homology-directed insertion into the genome using the engineered homing endonuclease ARCUS","volume":"53","author":"Resly","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omta.2026.201793_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10122029","article-title":"Long-Term Effects of Biliverdin Reductase a Deficiency in Ugt1(-\/-) Mice: Impact on Redox Status and Metabolism","volume":"10","author":"Bortolussi","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.omta.2026.201793_bib64","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/jimd.12068","article-title":"Comprehensive characterization of ureagenesis in the spf(ash) mouse, a model of human ornithine transcarbamylase deficiency, reveals age-dependency of ammonia detoxification","volume":"42","author":"Allegri","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omta.2026.201793_bib65","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/hgtb.2015.037","article-title":"Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system","volume":"26","author":"Meliani","year":"2015","journal-title":"Hum. Gene Ther. Methods"}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600128X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600128X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:17:56Z","timestamp":1789053476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X2600128X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X2600128X"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201793","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapamycin nanoparticles mitigate anti-AAV antibody formation in a mouse model of ornithine transcarbamylase deficiency","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201793"}}